Chemically Designed Functional Nanomicelles for Blood–Brain Barrier Crossing
Source abstract
Abstract
The blood–brain barrier (BBB) is a specialized semipermeable structure that restricts the exchange of materials between central nervous system parenchyma and blood vessels. Nanocarriers have shown the potential to cross the BBB via receptor-mediated transcytosis (RMT) or adsorption-mediated transcytosis (AMT), though efficiency remains limited. Here, we report two different polymer nanomicelles of 20–60 nm size that efficiently cross the BBB via either RMT or AMT. We have tested their performance in a transwell-based model, tumor spheroid model, and in vivo mice model. We found that lower numbers of receptors per nanomicelle are critical for RMT and direct membrane penetration property of nanomicelle is critical for AMT. Transcytosis can be enhanced by 8–10 times using the optimized nanomicelles that leads to 8 times enhanced penetration in tumor spheroid and 26–35 times enhanced delivery to deep brain tissue. These polymer nanomicelles can be used as nanocarrier for in vivo delivery of therapeutic biomolecules in brain.
Source: openalex_inverted_index · Quality: baseline
Research context
OpenAlex topics: Barrier Structure and Function Studies · Nanoparticle-Based Drug Delivery · Advanced Drug Delivery Systems
SciVX discovery tags are terminology-based. OpenAlex topics are source-provided classifications.
Affiliations
School of Materials Science
Indian Association for the Cultivation of Science
Department of Bioscience and Biotechnology
Indian Institute of Technology
Cellular and Molecular Neuroscience, National Brain Research Centre
Amity Institute of Biotechnology
Amity University
Funding
University Grants Commission · Science and Engineering Research Board
References (29)
Show source-provided references
1. 10.1016/j.nbd.2003.12.01610.1016/j.nbd.2003.12.016 ↗
2. 10.1124/pr.57.2.410.1124/pr.57.2.4 ↗
3. 10.1021/acs.molpharmaceut.4c0044710.1021/acs.molpharmaceut.4c00447 ↗
4. 10.1038/nrn182410.1038/nrn1824 ↗
5. 10.1021/acs.molpharmaceut.4c0060410.1021/acs.molpharmaceut.4c00604 ↗
6. 10.1016/j.pharmthera.2004.08.00110.1016/j.pharmthera.2004.08.001 ↗
7. 10.1016/j.bbcan.2010.04.00110.1016/j.bbcan.2010.04.001 ↗
8. 10.1038/nrclinonc.2011.5810.1038/nrclinonc.2011.58 ↗
9. 10.1016/j.jconrel.2016.05.04410.1016/j.jconrel.2016.05.044 ↗
10. 10.1038/s41392-023-01481-w10.1038/s41392-023-01481-w ↗
11. 10.1021/acsnano.3c1067410.1021/acsnano.3c10674 ↗
12. 10.1016/j.biomaterials.2019.11949110.1016/j.biomaterials.2019.119491 ↗
13. 10.1021/acs.nanolett.1c0299610.1021/acs.nanolett.1c02996 ↗
14. 10.1016/j.mattod.2020.02.00110.1016/j.mattod.2020.02.001 ↗
15. 10.1007/s00259-019-04347-y10.1007/s00259-019-04347-y ↗
16. 10.1021/ar900002610.1021/ar9000026 ↗
17. 10.1039/c0jm00994f10.1039/c0jm00994f ↗
18. 10.1038/s41598-020-75253-910.1038/s41598-020-75253-9 ↗
19. 10.1111/cns.1356910.1111/cns.13569 ↗
20. 10.1038/s41586-024-07314-210.1038/s41586-024-07314-2 ↗
21. 10.1081/DDC-12000148110.1081/DDC-120001481 ↗
22. 10.1007/s11095-007-9379-010.1007/s11095-007-9379-0 ↗
23. 10.1021/acs.accounts.1c0021510.1021/acs.accounts.1c00215 ↗
24. 10.1021/acsami.1c2200910.1021/acsami.1c22009 ↗
25. 10.1021/acsami.3c0924110.1021/acsami.3c09241 ↗
26. 10.1208/s12248-008-9055-210.1208/s12248-008-9055-2 ↗
27. 10.1073/pnas.130715211010.1073/pnas.1307152110 ↗
28. 10.1002/glia.2373410.1002/glia.23734 ↗
29. 10.1016/j.jconrel.2017.12.00510.1016/j.jconrel.2017.12.005 ↗